We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byBarbara Doddridge
Modified over 2 years ago
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination by Giulia Benevolo, Alessandra Stacchini, Michele Spina, Andrés J. M. Ferreri, Marcella Arras, Laura Bellio, Barbara Botto, Pietro Bulian, Maria Cantonetti, Lorella Depaoli, Nicola Di Renzo, Alice Di Rocco, Andrea Evangelista, Silvia Franceschetti, Laura Godio, Francesco Mannelli, Vincenzo Pavone, Pietro Pioltelli, Umberto Vitolo, and Enrico M. Pogliani Blood Volume 120(16):3222-3228 October 18, 2012 ©2012 by American Society of Hematology
Immunophenotyping and CC in a patient with DLBCL. FCM analysis shows the presence of 2 B- cell populations: one (black) of small polyclonal B lymphocytes and another (gray) of large monoclonal (κ-light chain positive) neoplastic B cells. Giulia Benevolo et al. Blood 2012;120:3222-3228 ©2012 by American Society of Hematology
PFS, OS, and cumulative incidence of CNS relapse. Giulia Benevolo et al. Blood 2012;120:3222-3228 ©2012 by American Society of Hematology
High Cure Rates of the Short-Term GITIL Chemotherapy Programme for Adult Patients with Burkitt Lymphoma by Jacopo Mariotti, Anna Guidetti, Michele Magni,
Validation of a flow cytometric scoring system as a prognostic indicator for posttransplantation outcome in patients with myelodysplastic syndrome by Bart.
Long-term outcome and prospective validation of NIH response criteria in 39 patients receiving imatinib for steroid-refractory chronic GVHD by Attilio.
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation.
Diffuse large B-cell lymphoma: reduced CD20 expression is associated with an inferior survival by Nathalie A. Johnson, Merrill Boyle, Ali Bashashati, Stephen.
Lymphoma dissemination: the other face of lymphocyte homing by Steven T. Pals, David J. J. de Gorter, and Marcel Spaargaren Blood Volume 110(9):
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program by Marco Ladetto,
Allogeneic stem cell transplantation for adult Philadelphia chromosome–negative acute lymphocytic leukemia: comparable survival rates but different risk.
Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk.
Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant.
Dasatinib as first-line treatment for adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia by Robin Foà, Antonella Vitale,
JAK2V617F mutation for the early diagnosis of Ph − myeloproliferative neoplasms in patients with venous thromboembolism: a meta-analysis by Francesco Dentali,
New criteria for response assessment: role of minimal residual disease in multiple myeloma by Bruno Paiva, Jacques J. M. van Dongen, and Alberto Orfao.
Pegylated interferon-α, ribavirin, and rituximab combined therapy of hepatitis C virus–related mixed cryoglobulinemia: a long-term study by Franco Dammacco,
Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome by Annamaria Brioli, Hannah Giles,
Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia by Alessandra Ferrajoli,
Maude et al. BLOOD, 25 JUNE 2015 x VOLUME 125, NUMBER 26
Improved outcome of adult Burkitt lymphoma/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial by Dieter Hoelzer,
Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de.
by Paul A. Carpenter, Meei-Li Huang, and George B. McDonald
© 2017 SlidePlayer.com Inc. All rights reserved.